171 related articles for article (PubMed ID: 38356427)
1. [Risks of magistral preparations in pediatrics].
Rosen C; Jacqmart C; Charlier C; Beghetti M; Seghaye MC
Rev Med Liege; 2024 Feb; 79(2):104-109. PubMed ID: 38356427
[TBL] [Abstract][Full Text] [Related]
2. Differences in the acute pulmonary vascular effects of oxygen with nitric oxide and diltiazem: implications for the long-term treatment of pulmonary arterial hypertension.
Day RW
Congenit Heart Dis; 2013; 8(1):71-7. PubMed ID: 22891699
[TBL] [Abstract][Full Text] [Related]
3. Calcium channel blockers in patients with pulmonary arterial hypertension receiving PAH-specific treatment.
Hirakawa K; Asano R; Ueda J; Aoki T; Tsuji A; Ogo T
Int J Cardiol; 2024 Jul; 406():132043. PubMed ID: 38614366
[TBL] [Abstract][Full Text] [Related]
4. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.
Sitbon O; Humbert M; Jagot JL; Taravella O; Fartoukh M; Parent F; Herve P; Simonneau G
Eur Respir J; 1998 Aug; 12(2):265-70. PubMed ID: 9727772
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension.
Tonelli AR; Alnuaimat H; Mubarak K
Respir Med; 2010 Apr; 104(4):481-96. PubMed ID: 20004088
[TBL] [Abstract][Full Text] [Related]
6. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
Beghetti M
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
[TBL] [Abstract][Full Text] [Related]
7. Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension: Current Clinical Practice From the TOPP Registry.
Douwes JM; Humpl T; Bonnet D; Beghetti M; Ivy DD; Berger RM;
J Am Coll Cardiol; 2016 Mar; 67(11):1312-23. PubMed ID: 26988953
[TBL] [Abstract][Full Text] [Related]
8. Calcium-channel blockers in pulmonary arterial hypertension.
Chaumais MC; Macari EA; Sitbon O
Handb Exp Pharmacol; 2013; 218():161-75. PubMed ID: 24092340
[TBL] [Abstract][Full Text] [Related]
9. Idiopathic pulmonary arterial hypertension in children.
Rosenzweig EB; Barst RJ
Curr Opin Pediatr; 2005 Jun; 17(3):372-80. PubMed ID: 15891429
[TBL] [Abstract][Full Text] [Related]
10. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
Hansmann G; Apitz C
Heart; 2016 May; 102 Suppl 2():ii67-85. PubMed ID: 27053700
[TBL] [Abstract][Full Text] [Related]
11. Evidence-based pharmacologic management of pulmonary arterial hypertension.
Benedict N; Seybert A; Mathier MA
Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
[TBL] [Abstract][Full Text] [Related]
12. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.
Madonna R; Cocco N; De Caterina R
Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders.
Halliday SJ; Hemnes AR; Robbins IM; Pugh ME; Zhao DX; Piana RN; Fong PP; Brittain EL
J Heart Lung Transplant; 2015 Mar; 34(3):312-8. PubMed ID: 25577565
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
Ruopp NF; Cockrill BA
JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
[TBL] [Abstract][Full Text] [Related]
15. The long-term response to treatment with calcium channel blockers in a patient with idiopathic pulmonary arterial hypertension.
Solik P; Lesny P; Luknar M; Varga I; Goncalvesova E
Bratisl Lek Listy; 2013; 114(5):283-6. PubMed ID: 23611052
[TBL] [Abstract][Full Text] [Related]
16. The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today?
Medarov BI; Judson MA
Respir Med; 2015 May; 109(5):557-64. PubMed ID: 25666253
[TBL] [Abstract][Full Text] [Related]
17. Current and advancing treatments for pulmonary arterial hypertension in childhood.
Zijlstra WM; Ploegstra MJ; Berger RM
Expert Rev Respir Med; 2014 Oct; 8(5):615-28. PubMed ID: 25047735
[TBL] [Abstract][Full Text] [Related]
18. Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension.
Saito Y; Nakamura K; Miyaji K; Akagi S; Mizoguchi H; Ogawa A; Fuke S; Fujio H; Kiyooka T; Nagase S; Kohno K; Morita H; Kusano KF; Matsubara H; Ohe T; Ito H
J Pharmacol Sci; 2012; 120(3):206-12. PubMed ID: 23117888
[TBL] [Abstract][Full Text] [Related]
19. Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).
Sobanski V; Launay D; Hachulla E; Humbert M
Curr Rheumatol Rep; 2016 Feb; 18(2):10. PubMed ID: 26841964
[TBL] [Abstract][Full Text] [Related]
20. [Current views on the use of vasodilators in pulmonary hypertension].
Ceriana P; De Amici D; Pagnin A; Braschi A
Minerva Cardioangiol; 1995 Jun; 43(6):273-9. PubMed ID: 7566540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
